Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials . J of Skin. 2022;6(6):s64. doi:10.25251/skin.6.supp.64